Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

48.40USD
17 Nov 2017
Change (% chg)

$0.65 (+1.36%)
Prev Close
$47.75
Open
$47.67
Day's High
$48.41
Day's Low
$47.65
Volume
897,051
Avg. Vol
804,520
52-wk High
$63.40
52-wk Low
$46.42

Chart for

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.16
Market Cap(Mil.): $7,442.75
Shares Outstanding(Mil.): 153.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA

* Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA

Nov 16 2017

BRIEF-ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA

* ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA

Oct 26 2017

BRIEF-ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24

* ‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​

Oct 26 2017

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million

Jul 27 2017

BRIEF-Alkermes announces positive preliminary topline results

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

Jun 29 2017

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

Jun 12 2017

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

Jun 08 2017

Competitors

Earnings vs. Estimates